新开利安生物科技（海南）有限公司借自贸港"东风"链接全球 打破国外技术垄断 产品远销16国 海南日报全媒体记者 武佳 辅酶Q10是人体细胞"能量工厂"（线粒体）的核心物质，有"细胞引擎"之称，其高效的"还原型"生 产技术曾长期被国外垄断。 破局之道，藏在一家2023年落户海口国家高新区药谷工业园的企业内。近日，走入新开利安生物科 技（海南）有限公司（以下简称新开利安）的结晶生产车间内，可见还原型辅酶Q10晶体正在反应釜内 有序成型。 作为国内唯一具有完全自主知识产权和完整体系认证的还原型辅酶Q10量产企业，新开利安的核心 竞争力源于其掌握的核心专利——"还原型辅酶Q10的晶型及其制备方法"。这一成果标志着中国企业首 次在辅酶Q10高端制造领域打破国外长达数十年的技术垄断，为国产原料进军全球市场奠定了关键知识 产权基础。 "这是我们生产过程中最重要的一步，也是打破垄断的核心所在。"近日，该公司总经理李论在结晶 生产车间向记者介绍，相较于传统氧化型产品，该技术制备的还原型辅酶Q10，无需体内转化即可直接 吸收利用，生物利用度和吸收利用率相较于氧化型辅酶Q10提升60%以上。 为什么会选择海南？ "选择海南，是新开 ...

Core Viewpoint - The health raw materials sector is evolving towards more precise, efficient, and personalized solutions, driven by technological advancements and regulatory improvements [3][7]. Group 1: Key Trends - The development and application of health raw materials are shifting from generalized "nutritional supplements" to refined solutions targeting specific demographics and health scenarios [3]. - Key trends include the upgrade to precision and scenario-based applications, focusing on specific health needs such as menopause care and metabolic management [3]. - The use of patented technologies, such as precision fermentation and advanced extraction processes, is enhancing the bioavailability and efficacy of raw materials, addressing previous cost and utilization challenges [3]. Group 2: Highlighted Raw Materials - Marine-derived active ingredients, such as phospholipid Omega-3 from krill oil, are noted for their significant effects on heart health, supported by pure Antarctic sources and patented technologies [3]. - Ergothioneine, while not yet approved as a new food ingredient in China, is widely used in the US, Europe, and Japan, showing promise in cosmetics and dietary supplements due to technological breakthroughs that alleviate scarcity and cost issues [3]. - Human milk oligosaccharides (HMOs) are gaining attention for their applications in infant formula and regular foods, with regulatory environments improving globally, including FDA approvals in the US and specific approvals in China [3][8]. - Reduced coenzyme Q10, enhanced through precision fermentation, is pushing nutritional supplements towards greater efficiency and precision [3]. Group 3: Market Dynamics - The market for health raw materials is increasingly focused on quality and transparency, with consumers prioritizing active ingredient content, standardization, and traceability [8]. - The cultivation of products using wild-simulated methods is gaining popularity due to balanced composition and high activity, making compliance and process transparency key competitive factors [8]. - Exosomes are emerging in regenerative medicine and precision healthcare, showing potential in areas like neurological disease repair and non-invasive tumor diagnostics, although most applications are still in early research stages [8].

Core Insights - Kaneka's participation in the China International Import Expo (CIIE) is a strategic move to align with China's "Healthy China 2030" initiative and tap into the growing health market in China [2][10] - The company aims to position itself not just as a raw material supplier but as a "value partner" for Chinese brands, providing comprehensive support in product development and market education [3][8] Company Strategy - Kaneka has over 45 years of research and development experience in coenzyme Q10, with more than 100 scientific studies and over 80 global patents backing its products [1][2] - The company recognizes the rapid upgrade of China's health consumption market and sees it as a core driver for global business growth [2][6] Product Offering - Kaneka's reduced form of coenzyme Q10 is produced using advanced Japanese fermentation technology, achieving global leadership in purity, stability, and bioavailability [3][4] - This product has a bioavailability that is 3-8 times higher than that of regular coenzyme Q10, allowing for direct absorption without conversion in the body [3][9] Quality Control - Kaneka maintains a stringent quality control system, ensuring that every batch of raw materials exceeds industry standards through scientific testing and third-party verification [4][7] - The company emphasizes consistency in quality, regardless of production scale, which has earned it the trust of over a thousand global brands [4][7] Market Education - Kaneka aims to educate the Chinese market about mitochondrial health, which is currently not widely recognized, by collaborating with medical professionals and social media influencers [5][10] - The company draws parallels to the rise in awareness of gut health over the past decade, hoping to make mitochondrial health a core concept among Chinese consumers [5][6] Target Demographics - The primary consumer group for Kaneka's coenzyme Q10 in China includes middle-aged and elderly individuals focused on cardiovascular health and energy metabolism [6][10] - There is also a growing segment of female consumers interested in reproductive health and skin improvement, indicating a broad market potential [6][10] Competitive Positioning - Compared to mature markets, Chinese consumers prioritize scientific evidence and brand reputation when selecting health products, aligning with Kaneka's product philosophy [7][10] - Kaneka plans to tailor its product solutions to meet local consumer needs while continuing to promote the benefits of its coenzyme Q10 [7][10] Future Directions - Kaneka sees significant potential in the mitochondrial health sector and aims to innovate continuously, exploring new applications for its coenzyme Q10 [9][10] - The company is committed to collaborating with global research institutions to expand its product development directions and enhance its market offerings [9][10]

Core Viewpoint - The company, Jindawei, has advanced production technology and scale, holding multiple invention patents, including reduced coenzyme Q10, in China and the United States [1] Group 1: Company Overview - Jindawei has a leading position in production technology and scale [1] - The company possesses several invention patents related to reduced coenzyme Q10 [1] Group 2: Market Analysis - The sales proportion of reduced coenzyme Q10 in the market is currently low [1] - The company has conducted research and analysis on the market prospects for reduced coenzyme Q10 [1]